GLP1R and diabetes mellitus: Since DPP-4 inhibitors are dependent on the endogenous secretion of incretins, that class of drugs will theoretically be useful in early stages of diabetes, when the patient still retains a β cell population capable of responding to GLP-1 stimulation.